PD-1 Inhibitor for Pancreatic Cancer

Recruiting in Palo Alto (17 mi)

+1 other location

Overseen byNilofer Azad, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

No Placebo Group

Prior Safety Data

Approved in 5 Jurisdictions

Trial Summary

What is the purpose of this trial?

This trial is testing INCMGA00012, a drug that boosts the immune system, in patients with severe pancreatic or ampullary cancer that cannot be removed by surgery or has spread. The goal is to see if this new treatment can help these patients.

Research Team

Nilofer Azad, MD

Principal Investigator

Johns Hopkins Medical Institution

Eligibility Criteria

This trial is for adults with advanced pancreatic or ampullary cancer that can't be surgically removed. Participants must have tried at least one chemotherapy, be in fairly good health (ECOG 0-1), and not have had more than two systemic treatments. They should expect to live more than three months, agree to biopsies, use birth control if applicable, and sign consent forms. People with certain medical conditions or recent treatments are excluded.

Inclusion Criteria

I have had 1 or 2 treatments for my condition, including chemotherapy.

My cancer is a specific type of pancreas or ampulla cancer.

I am HIV-positive, on effective treatment, with a CD4+ count ≥ 350 and an undetectable viral load.

See 10 more

Exclusion Criteria

I have a wound, ulcer, or bone fracture that is not healing.

You are using extra oxygen at home.

I have or had brain metastases.

See 21 more

Treatment Details

Interventions

INCMGA00012 (Monoclonal Antibodies)

Trial OverviewThe study tests INCMGA00012 (a PD-1 antibody) on patients who've previously treated their unresectable or metastatic adenosquamous pancreatic or ampullary cancer without success. It's a Phase 2 trial focusing on the effectiveness of this immunotherapy drug.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: INCMGA00012 (PD-1 antibody)Experimental Treatment1 Intervention

All participants will receive the interventional study drug; INCMGA00012.